Bone Marrow Transplantation

Lamivudine effective for post-transplant hepatitis B reactivation

Published in Hepatitis Weekly, April 1st, 2002

by Michael Greer, senior medical writer - The antiretroviral drug lamivudine can quickly resolve hepatitis B reinfection after bone marrow transplantation (BMT), researchers in Japan report.

"Reverse seroconversion of hepatitis B virus (HBV) after allogeneic BMT is rare," according to Dr. Satoshi Hashino and colleagues at the Hokkaido University Graduate School of Medicine in Sapporo.

Because HBV reactivation is uncommon, lamivudine treatment is probably more efficient than routine vaccination of bone marrow graft donors, Hashino and colleagues argued.

The researchers described the case of a 35-year-old women who underwent...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-04-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry